混合型肝细胞-胆管细胞癌主要成分的意义:MRI表现与预后价值
回顾性纳入两个中心300例慢性肝病患者(混合型肝细胞-胆管细胞癌、肝细胞癌、肝内胆管癌各100例),分析优势成分与MRI表现及无复发生存的关系。优势成分是混合型肝细胞-胆管细胞癌无复发生存的独立预测因子(HR=1.957,P=0.044);鉴别肝细胞癌优势型与肝细胞癌的模型AUC为0.756,鉴别胆管癌优势型与肝内胆管癌的模型AUC为0.898。
要点
- 优势成分是混合型肝细胞-胆管细胞癌无复发生存的独立预测因子(HR=1.957,P=0.044)。
- 靶样表现、缺乏强化包膜、动脉期瘤周强化提示肝细胞癌优势型混合型肝细胞-胆管细胞癌,联合AUC为0.756。
- 男性、AFP升高、CA19-9正常、强化包膜、出血、无靶样表现及无肝表面回缩提示胆管癌优势型,联合AUC为0.898。
核心结论
- 优势组织病理成分与混合型肝细胞-胆管细胞癌的影像表现密切相关,并具有显著预后作用,可能改变其无复发生存预后。
研究设计与样本
- 两中心回顾性纳入300例慢性肝病患者,混合型肝细胞-胆管细胞癌、肝细胞癌、肝内胆管癌各100例,均为手术病理证实;采用单因素和多因素回归分析筛选独立预测因子并构建诊断模型,比较组间无复发生存。
关键影像表现/征象
- 靶样表现、缺乏强化包膜和动脉期瘤周强化是提示肝细胞癌优势型混合型肝细胞-胆管细胞癌优于肝细胞癌的独立预测因子。
- 男性、较高的甲胎蛋白、正常的糖类抗原19-9、强化包膜、出血、无靶样表现和无肝表面回缩是提示胆管癌优势型混合型肝细胞-胆管细胞癌优于肝内胆管癌的独立预测因子。
诊断标准与关键数值
- 肝细胞癌优势型混合型肝细胞-胆管细胞癌 vs 肝细胞癌:靶样表现 OR=10.907(P=0.001),缺乏强化包膜 OR=0.072(P=0.001),动脉期瘤周强化 OR=0.091(P=0.003),联合AUC=0.756。
- 胆管癌优势型混合型肝细胞-胆管细胞癌 vs 肝内胆管癌:男性 OR=4.049(P=0.015),较高甲胎蛋白 OR=16.789(P<0.001),正常糖类抗原19-9 OR=0.343(P=0.036),强化包膜 OR=7.819(P<0.001),出血 OR=23.526(P=0.004),无靶样表现 OR=0.129(P=0.005),无肝表面回缩 OR=0.190(P=0.021),联合AUC=0.898。
- 优势成分预测无复发生存:HR=1.957(P=0.044)。
临床应用与阅片要点
- 阅片时关注靶样表现、强化包膜、动脉期瘤周强化、出血和肝表面回缩等征象,有助于提示混合型肝细胞-胆管细胞癌的优势成分。
- 肝细胞癌优势型混合型肝细胞-胆管细胞癌与肝细胞癌的无复发生存无显著差异(P=0.864)。
- 胆管癌优势型混合型肝细胞-胆管细胞癌的无复发生存较肝内胆管癌更差(P=0.009)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To investigate the significance of the predominant component of combined hepatocellular-cholangiocarcinoma (cHCC-CC) in terms of MRI manifestation and its potential prognostic value compared to hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC).
MATERIALS AND METHODS: A total of 300 patients with chronic liver disease from two centers were retrospectively enrolled, including 100 surgically proven cases of cHCC-CC, HCC, and ICC each. Univariate and multivariate regression analyses were performed to identify independent predictors for distinguishing HCC-predominant cHCC-CC and ICC-predominant cHCC-CC from HCC and ICC, respectively. Diagnostic models were constructed based on the independent features. Recurrence-free survival (RFS) was estimated and compared between groups.
RESULTS: The predominant component was an independent predictor for RFS in cHCC-CC (hazard ratio = 1.957, P = 0.044). The presence of targetoid appearance (odds ratio(OR) = 10.907, P = 0.001), lack of enhancing capsule (OR = 0.072, P = 0.001) and arterial peritumoral enhancement (OR = 0.091, P = 0.003) were independent predictors suggestive of HCC-predominant cHCC-CC over HCC; their combination yielded an area under the curve of 0.756. No significant differences were observed in RFS between HCC-predominant cHCC-CC and HCC (P = 0.864). Male gender (OR = 4.049, P = 0.015), higher alpha fetoprotein (OR = 16.789, P < 0.001) and normal carbohydrate antigen 19-9 (OR = 0.343, P = 0.036) levels, presence of enhancing capsule (OR = 7.819, P < 0.001) and hemorrhage (OR = 23.526, P = 0.004), and lack of targetoid appearance (OR = 0.129, P = 0.005) and liver surface retraction (OR = 0.190, P = 0.021) were independent predictors suggestive of ICC-predominant cHCC-CC over ICC; their combination yielded an area under the curve value of 0.898. ICC-predominant cHCC-CC exhibited poorer survival with shorter RFS than ICC (P = 0.009).
CONCLUSION: The predominant histopathological component is closely related to the imaging manifestation of cHCC-CC; and more importantly, it plays a significant prognostic role, which may alter the RFS prognosis of cHCC-CC.
引用
- Sheng R, Yang C, Zhang Y, et al. The significance of the predominant component in combined hepatocellular-cholangiocarcinoma: MRI manifestation and prognostic value. Radiol Med. 2023. PMID: 37474663. doi:10.1007/s11547-023-01682-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。